Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex

doi:10.1016/0197-4580(91)90106-T

Neurobiology of Aging

Volume 12, Issue 3, May–June 1991, Pages 255-258

https://doi.org/10.1016/0197-4580(91)90106-T Get rights and content

Abstract

Much evidence has accumulated to suggest that the peripheral type benzodiazepine (PBZ) binding site has a predominantly glial localization. Elevated PBZ binding densities have been reported in various models of brain damage, apparently reflecting glial proliferation in response to neurodegeneration. In the present study, PBZ receptor densities were examined in frontal and temporal cortex of Alzheimer's disease (AD) patients using the ligand [³H]PK 11195. There was a highly significant (p<0.01) increase in PBZ binding sites in the temporal cortex from AD patients. In the frontal cortex, a moderate increase was observed that approached statistical significance (p=-0.07). Decreased choline acetyltransferase activity was observed in both regions. These findings offer support for the potential use of the PBZ binding site as a marker for gliosis associated with neuronal cell death.

References (40)

BenavidesJ. et al.
Autoradiographic localization of peripheral benzodiazepine binding sites in the cat brain with [³H]PK 11195
Brain Res. Bull.
(1984)
BenavidesJ. et al.
Peripheral type benzodiazepine binding sites are a more sensitive index of excitotoxic lesions of the rat striatum than the neuronal marker enzymes choline acetyltransferase or glutamate decar☐ylase
Brain Res.
(1987)
Bjo¨rklundH. et al.
Short and long term effects of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes
Brain Res.
(1986)
CandyJ.M. et al.
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases
J. Neurol. Sci.
(1983)
DuboisA. et al.
Imaging of primary and remote ischaemic and excitotoxic brain lesions
LeFurG. et al.
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(methylpropyl)-3-isoquiisoquinoline-car☐amide
Life Sci.
(1983)
LowryO.H. et al.
Protein measurement with pholin phenol reagent
J. Biol. Chem.
(1951)
OwenF. et al.
[³H]Ro5-4864 and [³H]Ro5-4864 binding in kainate-lesioned rat striatum and temporal cortex of brains from patients with senile dementia of the Alzheimer type
Brain Res.
(1983)
SchoemakerH. et al.
Specific high affinity binding of [³h]Ro5-4864 to benzodiazepine binding sites in the rat cerebral cortex
Eur. J. Pharmacol.
(1981)
SchoemakerH. et al.
[³H]Ro5-4864 benzodiazepine binding in kainate lesioned striatum and Huntington's diseased basal ganglia
Brain Res.
(1982)

SelkoeD.J. et al.

Huntington's disease: changes in striatal proteins reflect astrocytic gliosis

Brain Res.

(1982)

BallM.J.

Neurofibrillary tangles and pathogenesis of dementia: a quantitative study

Neuropathol. Appl. Neurobiol.

(1976)

BenavidesJ. et al.

Labelling of “peripheral type” benzodiazepine receptors in the rat using [³H]PK 11195, an isoquinoline car☐amide derivative

BenavidesJ. et al.

Imaging of human brain lesions with a W3 site radioligand

Ann. Neurol.

(1988)

BenderA.S. et al.

Flunitrazepam binding to intact and homogenized astrocytes and neurons in primary culture

J. Neurochem.

(1984)

BlackK.L. et al.

Imaging of brain tumors using peripheral benzodiazepine receptor ligands

J. Neurosurg.

(1989)

BraestrupC. et al.

Specific benzodiazepine receptors in rat brain characterized by high affinity [³H]diazepam binding

CharbonneauP. et al.

Peripheral type benzodiazepine receptors in the living heart characterized by positron emission tomography

Circulation

(1986)

CiliaxB.J. et al.

In vivo imaging of rat C6 gliomas by [¹²⁵I]-iodinated benzodiazepines and isoquinolines

Soc. Neurosci. Abstr.

(1987)

ClarkeA. et al.

Altered expression of neuronal messenger RNA in Alzheimer cortex

Cited by (110)

Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with Alzheimer's disease
2023, Brain, Behavior, and Immunity
Glial activation is central to the pathogenesis of Alzheimer’s disease (AD). However, researchers have not demonstrated its relationship to longitudinal cognitive deterioration. We aimed to compare the prognostic effects of baseline positron emission tomography (PET) imaging of glial activation and amyloid/tau pathology on the successive annual cognitive decline in patients with AD.
We selected 17 patients diagnosed with mild cognitive impairment or AD. We assessed the annual changes in global cognition and memory. Furthermore, we assessed the predictive effects of baseline amyloid and tau pathology indicated by cerebrospinal fluid (CSF) concentrations and PET imaging of glial activation (¹¹C-DPA-713-binding potential in the area of Braak 1–3 [¹¹C-DPA-713-BP_ND]) on global cognition and memory using a stepwise regression analysis.
The final multiple regression model of annual changes in global cognition and memory scores included ¹¹C-DPA-713-BP_ND as the predictor. The CSF Aβ42/40 ratios and p-tau concentrations were removed from the final model. In stepwise Bayesian regression analysis, the Bayes factor-based model comparison suggested that the best model included ¹¹C-DPA-713-BP_ND as the predictor of decline in global cognition and memory.
Translocator protein–PET imaging of glial activation is a stronger predictor of AD clinical progression than the amount of amyloid/tau pathology measured using CSF concentrations. Glial activation is the primary cause of tau-induced neuronal toxicity and cognitive deterioration, thereby highlighting the potential of blocking maladaptive microglial responses as a therapeutic strategy for AD treatment.
TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward
2019, Pharmacology and Therapeutics
The use of Translocator Protein 18 kDa (TSPO) as a clinical neuroimaging biomarker of brain injury and neuroinflammation has increased exponentially in the last decade. There has been a furious pace in the development of new radiotracers for TSPO positron emission tomography (PET) imaging and its use has now been extensively described in many neurological and mental disorders. This fast pace of research and the ever-increasing number of new laboratories entering the field often times lack an appreciation of the historical perspective of the field and introduce dogmatic, but unproven facts, related to the underlying neurobiology of the TSPO response to brain injury and neuroinflammation. Paradoxically, while in neurodegenerative disorders and in all types of CNS pathologies brain TSPO levels increase, a new observation in psychiatric disorders such as schizophrenia is decreased brain levels of TSPO measured by PET. The neurobiological bases for this new finding is currently not known, but rigorous experimental design using multiple experimental approaches and careful interpretation of results is critically important to provide the methodological and/or biological underpinnings to this new observation. This review provides a perspective of the early history of validating TSPO as a biomarker of brain injury and neuroinflammation and a critical analysis of controversial topics in the literature related to the cellular sources of the TSPO response. The latter is important in order to provide the correct interpretation of PET studies in neurodegenerative and psychiatric disorders. Furthermore, this review proposes some yet to be explored explanations to new findings in psychiatric disorders and new approaches to quantitatively assess the glial sources of the TSPO response in order to move the field forward.
Metal complexes targeting the Translocator Protein 18 kDa (TSPO)
2017, Coordination Chemistry Reviews
Citation Excerpt :
Interestingly, TSPO is overexpressed in a variety of tumors (e.g., certain brain tumors, ovarian cancer, liver tumors, breast carcinoma, colorectal cancer, etc.) and its expression appears to be related to the degree of tumor malignancy [13–16]. In addition, TSPO is overexpressed on activated microglial cells localized in lesioned brain areas of patients with neurodegenerative or neuroinflammatory diseases like Alzheimer’s disease, Huntington’s disease, and multiple sclerosis [17,18]. Thus, TSPO has become an extremely attractive subcellular target not only to image but also to treat diseases overexpressing this protein (theranostic drugs combine in a single molecule the two functions i.e. they act both as a diagnostic and a therapeutic agent).
Since the discovery of antitumor activity of cisplatin in the late 60’s, the development of metal-based drugs has had an enormous burst with the aim of to increase the anti-cancer activity, lower side effects and promote specific accumulation to the target cells or organs. Indeed, a new discipline, called medicinal inorganic chemistry, has born where metal ions play a fundamental role. This review provides a comprehensive overview of various metal complexes targeting the Translocator Protein (TSPO), an 18 kDa high affinity cholesterol- and drug-binding protein found mostly in the outer mitochondrial membrane and formerly known as peripheral-type benzodiazepine receptor. TSPO distribution in healthy tissues varies considerably; in contrast, aberrant expression of TSPO has been noted in several pathological specimens including neurodegenerative diseases and cancers. These findings suggest that TSPO-targeted therapy and imaging may have utility in the treatment and visualization of diseases expressing high density of TSPO. In this review, potential applications in cancer diagnosis and therapy will be discussed.
Synthesis of [<sup>11</sup>C]PBR170, a novel imidazopyridine, for imaging the translocator protein with PET
2014, Applied Radiation and Isotopes
The translocator protein (TSPO) ligand 2-(6,8-dichloro-2-(4-ethoxyphenyl)imidazo[1,2-a]pyridin-3-yl)–N-(2-fluoropyridin-3-yl)–N-methylacetamide (PBR170), is a novel imidazopyridineacetamide with high affinity (2.6 nm) and selectivity for the TSPO. The synthesis of [¹¹C]PBR170 was accomplished by N-methylation of the corresponding desmethyl precursor with [¹¹C]methyl iodide in the presence of sodium hydroxide in dimethylformamide. [¹¹C]PBR170 was produced in 30–45% radiochemical yield (decay-corrected, based on [¹¹C]methyl iodide) with a radiochemical purity >98% and a specific activity of 90–190 GBq/μmol after 35 min of synthesis time.
The impact of oxidative stress in thiamine deficiency: A multifactorial targeting issue
2013, Neurochemistry International
Thiamine (vitamin B1) deficiency, the underlying cause of Wernicke–Korsakoff syndrome, is associated with the development of focal neuronal loss in vulnerable areas of the brain. Although the actual mechanism(s) that lead to the selective histological lesions characteristic of this disorder remain unresolved, oxidative stress has been shown to play a major role in its pathophysiology. In this review, the multifactorial influence of oxidative stress on a variety of processes known to take part in the development of structural lesions in TD including excitotoxicity, neuroinflammation, blood–brain barrier integrity, mitochondrial integrity, apoptosis, nucleic acid function, and neural stem cells will be discussed, and therapeutic strategies undertaken for treating neurodegeneration examined which may have an impact on the future treatment of this important vitamin deficiency.
Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [<sup>11</sup>C]DAA1106
2012, Psychiatry Research - Neuroimaging
Citation Excerpt :
The visualization of activated glial cells in the brain by positron emission tomography (PET) or single photon emission computed tomography (SPECT) was considered useful for investigating the role of the activation of glial cells in the disease process. Peripheral benzodiazepine receptors (PBR) were reported to reflect neuronal injury and inflammatory lesions in the brain by the increased expression of the number of binding sites in glial cells including activated microglia and reactive astrocytes, as previously indicated by autoradiography of Alzheimer's disease (AD) (Diorio et al., 1991; Kuhlmann and Guilarte, 2000). [11C]PK11195 and [123I]iodo-PK11195 are widely used to visualize PBR in the brain, and especially for the evaluation of lesions, by PET and SPECT, respectively (Hashimoto et al., 1989; Dumont et al., 1999).
Subjects with mild cognitive impairment (MCI) have “prodromal or incipient” dementia with neuropathological changes. Peripheral benzodiazepine receptor (PBR) binding was shown to reflect activated microglia, one of the predictive biomarkers of conversion to dementia. We sought to evaluate PBR binding in MCI subjects using positron emission tomography (PET). PET scans with [¹¹C]DAA1106, a potent and selective ligand for PBR, were performed on seven MCI subjects, 10 patients with Alzheimer's disease (AD) and 10 age-matched control subjects. PBR binding in the regions of interest was quantified by binding potential (BP). Five MCI subjects were clinically followed for 5 years after their initial PET scans. [¹¹C]DAA1106 binding to PBR was significantly increased in widespread areas in MCI subjects when compared to healthy controls. We found no significant difference in BP between MCI and AD patients. MCI subjects with [¹¹C]DAA1106 binding values higher than the control mean + 0.5 standard deviation (S.D.) developed dementia within 5 years. Our finding of higher DAA binding in MCI subjects indicated that microglial activation may occur before the onset of dementia. In vivo detection of microglial activation may provide useful prognostic information with respect to stratifying MCI subjects at increased risk of dementia.

View all citing articles on Scopus

¹: Dr. Sharon A. Welner, Douglas Hospital Research Centre, 6875 LaSalle Blvd., Verdun, Quebec, Canada, H4H 1R3.

View full text

Brief communicationPeripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex

Abstract

Brain Res. Bull.

Brain Res.

Brain Res.

J. Neurol. Sci.

Life Sci.

J. Biol. Chem.

Brain Res.

Eur. J. Pharmacol.

Brain Res.

Brain Res.

Neurofibrillary tangles and pathogenesis of dementia: a quantitative study

Neuropathol. Appl. Neurobiol.

Labelling of “peripheral type” benzodiazepine receptors in the rat using [3H]PK 11195, an isoquinoline car☐amide derivative

Imaging of human brain lesions with a W3 site radioligand

Ann. Neurol.

Flunitrazepam binding to intact and homogenized astrocytes and neurons in primary culture

J. Neurochem.

Imaging of brain tumors using peripheral benzodiazepine receptor ligands

J. Neurosurg.

Specific benzodiazepine receptors in rat brain characterized by high affinity [3H]diazepam binding

Peripheral type benzodiazepine receptors in the living heart characterized by positron emission tomography

Circulation

In vivo imaging of rat C6 gliomas by [125I]-iodinated benzodiazepines and isoquinolines

Soc. Neurosci. Abstr.

Altered expression of neuronal messenger RNA in Alzheimer cortex

Brief communication
Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex

Labelling of “peripheral type” benzodiazepine receptors in the rat using [³H]PK 11195, an isoquinoline car☐amide derivative

Specific benzodiazepine receptors in rat brain characterized by high affinity [³H]diazepam binding

In vivo imaging of rat C6 gliomas by [¹²⁵I]-iodinated benzodiazepines and isoquinolines